Table 3.
Comparison of variables between survivor and nonsurvivor groups in training set
| Variables | Survivor (n = 1172) | Non-survivor (n = 526) | P value |
|---|---|---|---|
| Age (IQR, year) | 65 (54–77) | 70 (60–83) | < 0.001 |
| Gender | 0.539 | ||
| Male (n, %) | 645 (55.8%) | 294 (55.9%) | |
| Female (n, %) | 527 (44.2%) | 232 (44.1%) | |
| Vital signs | |||
| DBP (mmHg) | 63 (52–73) | 62 (49–72) | 0.348 |
| SBP (mmHg) | 115 (98–130) | 113 (97–131) | 0.185 |
| HR (beats/min) | 96 (81–110) | 98 (82–112) | 0.187 |
| RR (beats/min) | 20 (16–24) | 21 (17–25) | 0.223 |
| Comorbidities | |||
| Renal diseases (n, %) | 96 (8.02%) | 53 (10.64%) | 0.117 |
| CAD (n, %) | 172 (14.68%) | 88 (16.73%) | 0.287 |
| Diabetes (n, %) | 74 (6.31%) | 29 (5.51%) | 0.728 |
| Hypertension (n, %) | 441 (37.62%) | 195 (37.07%) | 0.637 |
| laboratory characteristics | |||
| PLT (*109/L) | 234.0 (151.0–313.0) | 230.0 (122.7–302.0) | 0.121 |
| AST (IU/L) | 109.0 (23.0–70.0) | 374.0 (27.0–128.5) | < 0.001 |
| Sodium (mmol/L) | 137.0 (134.0–140.0) | 137.0 (133.0–141.0) | 0.757 |
| Glucose (mg/dL) | 154.0 (103.0–163.0) | 146.0 (99.0–165.0) | 0.164 |
| Chloride (mmol/L) | 102.0 (98.0–107.0) | 102.0 (97.0–107.0) | 0.751 |
| MCV (fL) | 90.0 (86.0–95.0) | 92.0 (88.0–98.0) | 0.001 |
| ALT (IU/L) | 73.0 (16.0–55.0) | 180.0 (17.0–74.5) | < 0.001 |
| Neutrophils (%) | 79.0 (74.4–89.0) | 77.0 (73.7–89.5) | 0.125 |
| Urea Nitrogen (mg/dL) | 32.0 (16.0–40.0) | 44.0 (22.0–57.0) | < 0.001 |
| PTT (s) | 34.0 (26.7–35.7) | 38.0 (28.4–41.5) | < 0.001 |
| Hematocrit (%) | 33.0 (29.0–37.6) | 33.0 (28.4–37.0) | 0.248 |
| PT (s) | 17.0 (13.2–17.5) | 20.0 (13.9–22.0) | < 0.001 |
| Anion Gap (mmol/L) | 16.0 (13.0–19.0) | 16.0 (14.0–20.0) | 0.267 |
| RDW (%) | 15.0 (13.9–16.6) | 16.0 (14.7–18.3) | < 0.001 |
| Lymphocytes (%) | 10.0 (4.4–13.3) | 11.0 (4.0–13.3) | 0.499 |
| WBC (*109/L) | 13.0 (7.8–17.0) | 13.0 (7.3–18.6) | 0.083 |
| NLR | 15.0 (5.6–18.8) | 15.0 (5.2–18.8) | 0.875 |
| Total calcium (mg/dL) | 8.0 (7.6–8.8) | 8.0 (7.5–8.8) | 0.196 |
| Lactate (mmol/L) | 2.0 (1.3–2.9) | 3.0 (1.7–3.9) | < 0.001 |
| Albumin (g/dL) | 3.0 (2.5–3.4) | 2.0 (2.3–3.1) | < 0.001 |
| Creatinine (mg/dL) | 1.0 (0.9–2.0) | 1.0 (0.9–2.2) | 0.238 |
| Total bilirubin (mg/dL) | 1.0 (0.4–1.2) | 3.0 (0.4–2.6) | < 0.001 |
| Scoring system | |||
| APACHEII (IQR) | 13 (10–16) | 15 (12–18) | < 0.001 |
| SOFA (IQR) | 2 (1–4) | 3 (2–5) | < 0.001 |
| Clinical outcomes | |||
| LOS in hospital (days) | 16 (6–20) | 8 (3–13) | < 0.001 |
SBP systolic blood pressure, DBP diastolic blood pressure, HR heart rate, RR respiratory rate, CAD coronary artery disease, WBC white blood cells, PLT platelet, RDW red cell volume distribution width, PT prothrombin time, PTT partial thrombin time, ALT alanine aminotransferase, AST aspartate aminotransferase, SOFA sequential organ failure assessment, APACHE acute physiology and chronic health evaluation, LOS length of stay, IQR interquartile ranges, MCV mean corpuscular volume, NLR is defined as the ratio of neutrophils to lymphocytes